A comprehensive understanding of the roles and interactions of PD-1 and PD-L1 within the tumor microenvironment of prostate cancer is imperative for the advancement of effective immunotherapeutic approaches and the enhancement of patient survival outcomes. Here, CD274 is linked to prostate carcinoma.